Kvols L K, Reubi J C
Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905.
Acta Oncol. 1993;32(2):197-201. doi: 10.3109/02841869309083912.
Patients with metastatic carcinoid tumors and the malignant carcinoid syndrome have benefited immensely from diagnostic and therapeutic advances during the past decade. Magnetic resonance imaging and whole body scintigraphy with radiolabelled analogues of somatostatin have improved our ability to diagnose, detect, stage and follow response to therapy. Surgical, medical, and radiation therapy may all contribute to the management of these patients. This disease is variable in its presenting symptoms and the biologic behavior of the tumor. The spectrum of clinical manifestations varies depending upon the type and quantity of polypeptide hormones or biogenic amines being produced. Although the tumors are usually indolent in their growth, the more dedifferentiated or anaplastic tumors can be quite aggressive. Thanks to new treatments that are very effective in the subgroup of anaplastic neuroendocrine carcinomas it is vital to recognize this subset. As research scientists and clinicians we must be aware of the natural history of the disease in order to optimize each patient's treatment. This highly selective review focuses on studies performed in collaboration with Dr. Charles Moertel along with other colleagues at the Mayo Clinic, have done in the past few years.
在过去十年中，转移性类癌肿瘤和恶性类癌综合征患者从诊断和治疗进展中受益匪浅。磁共振成像以及使用放射性标记的生长抑素类似物进行的全身闪烁扫描，提高了我们诊断、检测、分期以及跟踪治疗反应的能力。手术、药物和放射治疗都可能有助于这些患者的管理。这种疾病的症状表现和肿瘤的生物学行为各不相同。临床表现的范围取决于所产生的多肽激素或生物胺的类型和数量。尽管肿瘤通常生长缓慢，但分化程度较低或间变的肿瘤可能具有相当的侵袭性。由于新的治疗方法在间变性神经内分泌癌亚组中非常有效，识别这一亚组至关重要。作为研究科学家和临床医生，我们必须了解该疾病的自然史，以便优化每位患者的治疗。这篇高度选择性的综述重点关注了过去几年与梅奥诊所的查尔斯·莫特尔博士以及其他同事合作开展的研究。
